135 related articles for article (PubMed ID: 23527729)
1. Short-term tolerability of morniflumate in patients with cutaneous hypersensitivity reactions to non-steroidal anti-inflammatory drugs.
Mero F; Nettis E; Aloia AM; Di Leo E; Ferrannini A; Vacca A
Int J Immunopathol Pharmacol; 2013; 26(1):247-50. PubMed ID: 23527729
[TBL] [Abstract][Full Text] [Related]
2. Morniflumate-induced urticaria-angioedema.
Matheu V; Sierra Z; Gracia MT; Caloto M; Alcazar MM; Martinez MI; Zapatero L
Allergy; 1998 Aug; 53(8):812-3. PubMed ID: 9722233
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of morniflumate for the treatment of symptoms associated with soft tissue inflammation.
Cremonesi G; Cavalieri L
J Int Med Res; 2015 Jun; 43(3):290-302. PubMed ID: 25921871
[TBL] [Abstract][Full Text] [Related]
4. Double-blind, placebo-controlled multicentre trial of the efficacy and tolerance of morniflumate suppositories in the treatment of tonsillitis in children.
Manach Y; Ditisheim A
J Int Med Res; 1990; 18(1):30-6. PubMed ID: 2110537
[TBL] [Abstract][Full Text] [Related]
5. [A new anti-inflammatory-analgesic-antipyretic, morniflumate, in the treatment of chronic recurring bronchitis].
Melica A; Donateo L; Gerardi R; Parenti M
Riv Eur Sci Med Farmacol; 1991; 13(1-2):51-60. PubMed ID: 1796197
[TBL] [Abstract][Full Text] [Related]
6. [Controlled clinical study on the use of morniflumate in the treatment of inflammatory-degenerative diseases of the locomotor system].
Raffaetà G; Saponati G; Terzuoli A
G Clin Med; 1987 Oct; 68(10):507-13. PubMed ID: 3428515
[No Abstract] [Full Text] [Related]
7. Simultaneous determination of morniflumate and its major active metabolite, niflumic acid, in human plasma by high-performance liquid chromatography in stability and pharmacokinetic studies.
Cho HY; Park GK; Lee YB
Biomed Chromatogr; 2013 Nov; 27(11):1438-43. PubMed ID: 23722315
[TBL] [Abstract][Full Text] [Related]
8. Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.
Liccardi G; Salzillo A; Piccolo A; Senna G; Piscitelli E; D'Amato M; D'Amato G
Eur Ann Allergy Clin Immunol; 2005 Feb; 37(2):50-3. PubMed ID: 15859361
[TBL] [Abstract][Full Text] [Related]
9. Short-term tolerability of etoricoxib in patients with cutaneous hypersensitivity reactions to nonsteroidal anti-inflammatory drugs.
Nettis E; Colanardi MC; Ferrannini A; Vacca A; Tursi A
Ann Allergy Asthma Immunol; 2005 Nov; 95(5):438-42. PubMed ID: 16312166
[TBL] [Abstract][Full Text] [Related]
10. A gastroprotective anti-inflammatory agent: the beta-morpholinoethyl ester of niflumic acid (morniflumate).
Schiantarelli P; Cadel S; Acerbi D
Agents Actions; 1984 Feb; 14(2):247-56. PubMed ID: 6608862
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of acute inflammatory pathology of the upper airway with morniflumate].
Marchioni CF; Livi E; Oliani C; Guerzoni P; Corona M
Riv Eur Sci Med Farmacol; 1990 Dec; 12(6):347-57. PubMed ID: 2132289
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous reactions to non-steroidal anti-inflammatory drugs.
Kasemsarn P; Kulthanan K; Tuchinda P; Dhana N; Jongjarearnprasert K
J Drugs Dermatol; 2011 Oct; 10(10):1160-7. PubMed ID: 21968666
[TBL] [Abstract][Full Text] [Related]
13. Provocation tests with the offending nonsteroidal anti-inflammatory drugs in patients with urticaria/angioedema reactions.
Zisa G; Riccobono F; Bommarito L; D'Antonio C; Calamari AM; Poppa M; Moschella MA; Di Pietrantonj C; Galimberti M
Allergy Asthma Proc; 2012; 33(5):421-6. PubMed ID: 23026184
[TBL] [Abstract][Full Text] [Related]
14. [Lyell syndrome following administration of erythromycin-sulfafurazole and morniflumate].
Raymond F; Paillat A; Gambert C; Garnier P
Arch Pediatr; 1995 May; 2(5):494-5. PubMed ID: 7640747
[No Abstract] [Full Text] [Related]
15. Patient-reported multiple drug reactions: clinical profile and results of challenge testing.
Ramam M; Bhat R; Jindal S; Kumar U; Sharma VK; Sagar R; Chadda RK
Indian J Dermatol Venereol Leprol; 2010; 76(4):382-6. PubMed ID: 20657119
[TBL] [Abstract][Full Text] [Related]
16. Long-term tolerability of etoricoxib in patients with previous reactions to non-steroidal anti-inflammatory drugs.
Di Leo E; Aloia AM; Nettis E; Cardinale F; Foti C; Distaso M; Ferrannini A; Vacca A
Int J Immunopathol Pharmacol; 2009; 22(4):1131-4. PubMed ID: 20074479
[TBL] [Abstract][Full Text] [Related]
17. Oral challenge in patients with suspected cutaneous adverse drug reactions: findings in 784 patients during a 25-year-period.
Lammintausta K; Kortekangas-Savolainen O
Acta Derm Venereol; 2005; 85(6):491-6. PubMed ID: 16396795
[TBL] [Abstract][Full Text] [Related]
18. Incidence of mucocutaneous reactions in children treated with niflumic acid, other nonsteroidal antiinflammatory drugs, or nonopioid analgesics.
Sturkenboom M; Nicolosi A; Cantarutti L; Mannino S; Picelli G; Scamarcia A; Giaquinto C;
Pediatrics; 2005 Jul; 116(1):e26-33. PubMed ID: 15930187
[TBL] [Abstract][Full Text] [Related]
19. Niflumic acid and mucocutaneous reactions.
Menniti-Ippolito F; Traversa G; Da Cas R; Leone R; Caputi A
Pediatrics; 2006 Jan; 117(1):253-4; author reply 254-5. PubMed ID: 16396893
[No Abstract] [Full Text] [Related]
20. Patch testing in the investigation of non-immediate cutaneous adverse drug reactions to metamizole.
Pinho A; Santiago L; Gonçalo M
Contact Dermatitis; 2017 Apr; 76(4):238-239. PubMed ID: 28317195
[No Abstract] [Full Text] [Related]
[Next] [New Search]
